Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

MAY 22, 2023

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.

Immune Response 107

Immune Response Vaccine Vaccination Trials 107

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 96

Immune Response Protein Vaccine Vaccination 96

BioSpace

SEPTEMBER 1, 2020

There is new research out of Iceland that suggests the body’s immune response to COVID-19 lasts longer than other research has suggested.

Immune Response 113

Immune Response Antibody Research 113

Scienmag

JULY 8, 2022

Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The interdisciplinary study, published in Science Immunology, revealed how changing the flexibility of the antibody could stimulate a stronger immune response.

Antibody 86

Antibody Immune Response Scientist Research 86

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. This response was also seen in the RV 144 trial, she notes.

Vaccine 293

Vaccine Vaccination Antibody Trials 293

XTalks

NOVEMBER 12, 2024

Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies. Monoclonal Antibody Therapies Monoclonal antibodies are gaining traction as targeted treatments for bacterial and viral infections.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

World of DTC Marketing

APRIL 11, 2021

Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. . If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccine Vaccination Antibody 69

Medical Xpress

NOVEMBER 8, 2022

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Immune Response 72

Immune Response Vaccine Vaccination Antibody 72

pharmaphorum

FEBRUARY 25, 2021

Maryland, US-based company Altimmune is among the biotechs and research labs trying to find more convenient alternatives and believes a nasal vaccine spray that is stable at room temperature could be the answer. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

Pharmaceutical Technology

AUGUST 5, 2022

The scientific approach of MiroBio for immune balance restoration to treat autoimmune diseases complements the inflammation research and development works of Gilead. MB272, the lead investigational antibody of MiroBio, is a selective immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) agonist.

Antibody 130

Antibody Immune Response Clinical Trials Clinical Trials 130

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Microenvironment Management : Optimizing the tumor microenvironment to enhance TIL efficacy remains a critical focus of research efforts.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Pharmaceutical Technology

MAY 12, 2023

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Development 130

Development Antibody Immune Response Genome 130

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. It will then computationally re-assemble antigen-antibody pairs as potential starting points for the development of drugs.

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130

XTalks

OCTOBER 12, 2021

The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Antibody 130

XTalks

APRIL 1, 2025

It occurs when immune cells from the donor perceive the host tissues as foreign and subsequently initiate an immune response against them. Despite the use of corticosteroids as the standard first-line treatment, many patients fail to achieve a sustained response, leading to high rates of morbidity and mortality.

Immune Response 59

Immune Response Trials Licensing Licensing 59

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

pharmaphorum

JUNE 29, 2021

The Com-COV trial compared two shots with Pfizer/BioNTech’s Comirnaty, two doses of AstraZeneca’s Vaxzevria, and a mixed regimen of one of each jab, and found that all were effective at stimulating a “robust” immune response against the coronavirus, according to the investigators.

Immune Response 128

Immune Response Vaccine Vaccination Antibody 128

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. “The authors acknowledge certain limitations of the study, including small numbers of participants.

Vaccine 116

Vaccine Vaccination Immune Response Development 116

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. .

Immune Response 52

Immune Response Vaccine Vaccination RNA 52

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach. They will be followed for six months to gauge the safety and immunogenicity of the vaccine.

Vaccine 145

Vaccine Vaccination Trials Immune Response 145

STAT News

DECEMBER 23, 2022

The new drug, called Lunsumio, is a so-called bispecific antibody, which works by attaching to cancer cells with one arm of the drug, and T cells with a second arm. In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response.

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

XTalks

AUGUST 8, 2022

MiroBio’s Research Pursuits. MiroBio is a private biotech company based in the UK that focuses on developing checkpoint agonist antibodies, which are a new class of therapies that work to restore immune balance in patients with autoimmune and inflammatory diseases.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Scienmag

MARCH 24, 2022

People who were infected with SARS-CoV-2 before being vaccinated generate an immune response more specific to fighting viral infections, and produce a broader antibody response, than do people whose only protection is the vaccine, according to researchers at the University of Washington School of Medicine.

Immune Response 79

Immune Response Vaccine Vaccination Antibody 79

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccine 75

Vaccine Vaccination Immune Response Containment 75

pharmaphorum

NOVEMBER 25, 2022

Rather than completely preventing infections, the aim would be to stimulate a memory immune response that could be quickly recalled and adapted to new pandemic viral strains. The post mRNA can deliver universal flu vaccine, say US researchers appeared first on.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

Scienmag

MAY 6, 2022

New research being presented at this year’s European Congress on Obesity (ECO) in Maastricht, Netherlands (4-7 May), suggests that adults (aged 18 or older) with severe obesity generate a significantly weaker immune response to COVID-19 vaccination compared to those with normal weight.

Vaccine 59

Vaccine Vaccination Immune Response Antibody 59

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. The FDA granted Regeneron’s antibody cocktail Emergency Use Authorization in November. Source link.

Antibody 52

Antibody Immune Response Clinical Trials Clinical Trials 52

Pharmaceutical Technology

DECEMBER 6, 2022

In the partnership’s discovery phase, RAVEN, an artificial intelligence (AI) platform of Evaxion will be leveraged for designing a next-generation vaccine candidate that induces cellular as well as humoral/antibody responses. Using ExpreS 2 ion’s ExpreS2 platform, the company will manufacture the antigen constructs obtained from RAVEN.

Vaccine 130

Vaccine Vaccination Development Immune Response 130

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We

Immune Response 40

Immune Response Vaccine Vaccination Clinical Trials 40